Please login to the form below

Not currently logged in
Email:
Password:

product launches

This page shows the latest product launches news and features for those working in and with pharma, biotech and healthcare.

Solid Q1 results lift Pfizer as it waits for pipeline boost

Solid Q1 results lift Pfizer as it waits for pipeline boost

That will come on the back of product launches like tafamidis in rare disease transthyretin amyloid cardiomyopathy, a trio of recently-approved cancer drugs including Vizimpro (dacomitinib), a rival to ... to bring an extended 20-valent product to market,

Latest news

  • BMS closes on Celgene merger after rebel investors bow out BMS closes on Celgene merger after rebel investors bow out

    It went on: “The combined company will be stronger today, and better positioned for sustainable long-term growth, with six expected near-term product launches, strong commercialisation capabilities, and a deep

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    Roche said it thinks the same pattern will be evident this year, however, with new product growth outweighing declines for MabThera, Herceptin and Avastin (bevacizumab), which together account for more than ... Based on the successful launches and our

  • BMS and Celgene announce $74bn merger BMS and Celgene announce $74bn merger

    Its late-stage pipeline will include six expected near-term product launches, and BMS says Celgene's pipeline can contribute around $15 bn in near-term annual revenue.

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    product that has brought in more than $100bn in sales since its launch in 2001. ... to an explosion of new studies and product launches in immuno-oncology.

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    most important new product launches. ... The new product is still very much in its roll-out phase after getting FDA approval in September 2017 but, according to GSK, is off to a “strong start” with £11m (

More from news
Approximately 0 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    PME talks to its European leader Theresa Heggie. Even as it launches its first ever product Onpattro, Alnylam is already a biotech industry case study. ... and sustainable clinical pipeline and a robust product engine by the end of 2020; a company

  • Positive disruption in business intelligence Positive disruption in business intelligence

    During the years before a product launches, HCP ‘digital opinion leaders’ - online HCP influencers in a particular therapy area - may be identified who are advocating for a new product in development. ... Tactical opportunities. Listening to HCPs’

  • Beyond the annual plan Beyond the annual plan

    In the last five years, the pharmaceutical industry has shifted from blockbusters in primary care to an increased number of high value specialty launches. ... This means more product launches in more indications, marketed to larger audiences than ever

  • ‘Dear Pharma, stop talking, start delivering’ ‘Dear Pharma, stop talking, start delivering’

    Hence, the resulting services and apps cater to one specific product or perhaps one disease. ... Reap the launch opportunity: Product launches allow leveraging global resources for developing an effective and globally scalable engagement programme.

  • The new launch paradigm The new launch paradigm

    To this end, it is imperative that new product launches are executed flawlessly and complement the overall corporate objective for consistent, successful multiple-product launches. ... More positively, the increasing recent and ongoing investment in

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Novo Nordisk target Ablynx reshuffles its board Novo Nordisk target Ablynx reshuffles its board

    Hensen is the ideal person to lead the board moving forward and his wealth of experience is particularly relevant as we advance towards the potential approvals and global launches of our ... lead, wholly-owned product, caplacizumab, in addition to

  • Astellas promotes John Demaree Astellas promotes John Demaree

    In his new role, Demaree will lead the promotion of in-market products, the preparation of product launches and will collaborate with Astellas' partner organisations in the region on marketing strategy.

  • The Medicines Company appoints Biogen's Tony Kingsley The Medicines Company appoints Biogen's Tony Kingsley

    Kingsley previously served as Biogen's executive vice president, global commercial operations, where the product launches he oversaw included the multiple sclerosis blockbuster Tecfidera (dimethyl fumerate).

  • Coloplast appoints new learning and development manager Coloplast appoints new learning and development manager

    Michelle has over 17 years of experience in training and development which involved systems training, training for new hires and product launches.

  • Nabriva Therapeutics adds Will Sargent to team Nabriva Therapeutics adds Will Sargent to team

    Sargent has over twenty years of experience in the biopharmaceutical industry, including multiple product and line extension launches. ... Nabriva is currently moving rapidly to advance its lead product, lefamulin, into phase III clinical studies which

More from appointments
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 48 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics